JP2009535422A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009535422A5 JP2009535422A5 JP2009510011A JP2009510011A JP2009535422A5 JP 2009535422 A5 JP2009535422 A5 JP 2009535422A5 JP 2009510011 A JP2009510011 A JP 2009510011A JP 2009510011 A JP2009510011 A JP 2009510011A JP 2009535422 A5 JP2009535422 A5 JP 2009535422A5
- Authority
- JP
- Japan
- Prior art keywords
- implant
- biodegradable
- vasoactive
- vasodilator
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007943 implant Substances 0.000 claims 17
- 230000002227 vasoactive effect Effects 0.000 claims 5
- 229940124549 vasodilator Drugs 0.000 claims 5
- 239000003071 vasodilator agent Substances 0.000 claims 5
- 229920002988 biodegradable polymer Polymers 0.000 claims 4
- 239000004621 biodegradable polymer Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229920000747 poly(lactic acid) Polymers 0.000 claims 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 2
- 230000004438 eyesight Effects 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 201000004569 Blindness Diseases 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 102000002045 Endothelin Human genes 0.000 claims 1
- 108050009340 Endothelin Proteins 0.000 claims 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 229920002732 Polyanhydride Polymers 0.000 claims 1
- 206010057430 Retinal injury Diseases 0.000 claims 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims 1
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000000593 degrading effect Effects 0.000 claims 1
- 238000012377 drug delivery Methods 0.000 claims 1
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- DQJJMWZRDSGUJP-UHFFFAOYSA-N ethenoxyethene;furan-2,5-dione Chemical compound C=COC=C.O=C1OC(=O)C=C1 DQJJMWZRDSGUJP-UHFFFAOYSA-N 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000003551 muscarinic effect Effects 0.000 claims 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 1
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 claims 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 229920000515 polycarbonate Polymers 0.000 claims 1
- 239000004417 polycarbonate Substances 0.000 claims 1
- 239000000622 polydioxanone Substances 0.000 claims 1
- 229920002643 polyglutamic acid Polymers 0.000 claims 1
- 229920000903 polyhydroxyalkanoate Polymers 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 230000002040 relaxant effect Effects 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000050 smooth muscle relaxant Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 239000002550 vasoactive agent Substances 0.000 claims 1
- 230000024883 vasodilation Effects 0.000 claims 1
- 230000004304 visual acuity Effects 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
- 210000004127 vitreous body Anatomy 0.000 claims 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/417,420 US20070260203A1 (en) | 2006-05-04 | 2006-05-04 | Vasoactive agent intraocular implant |
| PCT/US2007/067883 WO2007130945A1 (en) | 2006-05-04 | 2007-05-01 | A sustained-release intraocular implant comprising a vasoactive agent |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013170156A Division JP2014014694A (ja) | 2006-05-04 | 2013-08-20 | 血管拡張薬を含有する持続放出性眼内インプラント |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009535422A JP2009535422A (ja) | 2009-10-01 |
| JP2009535422A5 true JP2009535422A5 (https=) | 2010-06-24 |
Family
ID=38508941
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009510011A Pending JP2009535422A (ja) | 2006-05-04 | 2007-05-01 | 血管作動薬を含有する持続放出性眼内インプラント |
| JP2013170156A Pending JP2014014694A (ja) | 2006-05-04 | 2013-08-20 | 血管拡張薬を含有する持続放出性眼内インプラント |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013170156A Pending JP2014014694A (ja) | 2006-05-04 | 2013-08-20 | 血管拡張薬を含有する持続放出性眼内インプラント |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20070260203A1 (https=) |
| EP (1) | EP2026764B1 (https=) |
| JP (2) | JP2009535422A (https=) |
| AU (1) | AU2007248143B2 (https=) |
| BR (1) | BRPI0711311A2 (https=) |
| CA (1) | CA2651300C (https=) |
| DK (1) | DK2026764T3 (https=) |
| WO (1) | WO2007130945A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| AU2002236495B2 (en) | 2000-11-29 | 2006-05-11 | Allergan, Inc. | Intraocular implants for preventing transplant rejection in the eye |
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| US20050048099A1 (en) | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US20070178138A1 (en) * | 2006-02-01 | 2007-08-02 | Allergan, Inc. | Biodegradable non-opthalmic implants and related methods |
| US9849027B2 (en) | 2007-11-08 | 2017-12-26 | Alimera Sciences, Inc. | Ocular implantation device |
| DE102008040786A1 (de) * | 2008-07-28 | 2010-02-04 | Biotronik Vi Patent Ag | Biokorrodierbares Implantat mit einer Beschichtung enthaltend eine wirkstofftragende Polymermatrix |
| US20100204325A1 (en) * | 2009-02-11 | 2010-08-12 | Allergan, Inc. | Valproic acid drug delivery systems and intraocular therapeutic uses thereof |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| CA3186189A1 (en) | 2009-05-18 | 2010-11-25 | Dose Medical Corporation | Drug eluting ocular implant |
| US8529492B2 (en) | 2009-12-23 | 2013-09-10 | Trascend Medical, Inc. | Drug delivery devices and methods |
| CA2798084A1 (en) | 2010-05-17 | 2011-11-24 | Aerie Pharmaceuticals, Inc. | Drug delivery devices for delivery of ocular therapeutic agents |
| US9668915B2 (en) | 2010-11-24 | 2017-06-06 | Dose Medical Corporation | Drug eluting ocular implant |
| US20120276186A1 (en) * | 2011-04-29 | 2012-11-01 | Ghebremeskel Alazar N | Sustained release latanoprost implant |
| US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
| US8883189B2 (en) | 2011-09-27 | 2014-11-11 | The Regents Of The University Of Colorado, A Body Corporate | Intraocular encapsulation of oxygenic bacteria |
| CN109602691A (zh) * | 2013-02-15 | 2019-04-12 | 阿勒根公司 | 持续药物递送植入物 |
| EP3677229A1 (en) | 2014-05-29 | 2020-07-08 | Glaukos Corporation | Implants with controlled drug delivery features |
| US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
| WO2017053885A1 (en) | 2015-09-25 | 2017-03-30 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| EP3442479B1 (en) | 2016-04-20 | 2026-03-04 | Glaukos Corporation | Bioresorbable ocular drug delivery device |
| US11690806B2 (en) | 2018-05-24 | 2023-07-04 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
| KR20260007295A (ko) | 2018-05-24 | 2026-01-13 | 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 | 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치 |
| US11689849B2 (en) | 2018-05-24 | 2023-06-27 | Nureva, Inc. | Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones |
| EP3893918B1 (en) * | 2018-12-10 | 2024-09-25 | Rigshospitalet | Vasodilators for use in the treatment of a retinal ischemic disorder |
| GB2601922B (en) | 2019-06-27 | 2024-04-24 | Layerbio Inc | Ocular device drub delivery systems |
| WO2021087399A1 (en) | 2019-10-30 | 2021-05-06 | Perfuse Therapeutics, Inc. | Treatment of ocular diseases using endothelin receptor antagonists |
| US12226452B2 (en) * | 2020-03-04 | 2025-02-18 | The Schepens Eye Research Institute, Inc. | Polyhedrin-based slow release growth factor system for neuroprotection of retinal ganglion cell neurons |
| BR112023022439A2 (pt) | 2021-04-26 | 2023-12-26 | Celanese Eva Performance Polymers Llc | Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular |
| CA3218251A1 (en) | 2021-04-30 | 2022-11-03 | Perfuse Therapeutics, Inc. | Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases |
| AU2022264438A1 (en) * | 2021-04-30 | 2023-11-23 | Perfuse Therapeutics, Inc. | Treatment of ocular diseases using endothelin receptor antagonists |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| JPS58126435U (ja) * | 1982-02-19 | 1983-08-27 | オリンパス光学工業株式会社 | Ｔｔｌオ−トストロボ用絞り制御回路 |
| US4521210A (en) * | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
| US4853224A (en) * | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
| US4997652A (en) * | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US5164188A (en) * | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| KR0185215B1 (ko) * | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| US5443505A (en) * | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US6369116B1 (en) * | 1995-06-02 | 2002-04-09 | Oculex Pharmaceuticals, Inc. | Composition and method for treating glaucoma |
| US6306426B1 (en) * | 1997-08-11 | 2001-10-23 | Allergan Sales, Inc. | Implant device with a retinoid for improved biocompatibility |
| CA2300154C (en) * | 1997-08-11 | 2008-07-08 | Allergan Sales, Inc. | Sterile bioerodible implant device with improved biocompatability and method |
| US6331313B1 (en) * | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| US6726918B1 (en) * | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| AU2002236495B2 (en) * | 2000-11-29 | 2006-05-11 | Allergan, Inc. | Intraocular implants for preventing transplant rejection in the eye |
| AP1893A (en) * | 2000-12-01 | 2008-09-23 | Osi Pharm Inc | Compounds specific to adenosine A1, A2A and A3 receptor and uses thereof |
| US6713081B2 (en) * | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
| US20050203542A1 (en) * | 2002-09-18 | 2005-09-15 | Allergan, Inc. | Apparatus for delivery of ocular implants with reduced incidence of ocular adverse events |
| US7468065B2 (en) * | 2002-09-18 | 2008-12-23 | Allergan, Inc. | Apparatus for delivery of ocular implants |
| US6899717B2 (en) * | 2002-09-18 | 2005-05-31 | Allergan, Inc. | Methods and apparatus for delivery of ocular implants |
| US20040137059A1 (en) * | 2003-01-09 | 2004-07-15 | Thierry Nivaggioli | Biodegradable ocular implant |
| US20050048099A1 (en) * | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| US20050101582A1 (en) * | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| WO2005110374A1 (en) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| US20050244478A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Anti-excititoxic sustained release intraocular implants and related methods |
| US20050244471A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Estradiol derivative and estratopone containing sustained release intraocular implants and related methods |
| US7771742B2 (en) * | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| US20050244458A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
| US7799336B2 (en) * | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US8512738B2 (en) * | 2004-04-30 | 2013-08-20 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase implants |
| US20050244469A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US8685435B2 (en) * | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| AU2005240078A1 (en) * | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing |
| US8425929B2 (en) * | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| US8119154B2 (en) * | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| DE102004023069A1 (de) * | 2004-05-11 | 2005-12-08 | Bayer Healthcare Ag | Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil |
| BRPI0516308A2 (pt) * | 2004-10-04 | 2010-06-15 | Qlt Usa Inc | composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida |
| CA2615360A1 (en) * | 2005-07-15 | 2007-01-25 | Chakshu Research Inc. | Formulation and method for administration of ophthalmologically active agents |
-
2006
- 2006-05-04 US US11/417,420 patent/US20070260203A1/en not_active Abandoned
-
2007
- 2007-05-01 BR BRPI0711311-0A patent/BRPI0711311A2/pt not_active IP Right Cessation
- 2007-05-01 AU AU2007248143A patent/AU2007248143B2/en not_active Ceased
- 2007-05-01 WO PCT/US2007/067883 patent/WO2007130945A1/en not_active Ceased
- 2007-05-01 EP EP07761644.9A patent/EP2026764B1/en not_active Not-in-force
- 2007-05-01 JP JP2009510011A patent/JP2009535422A/ja active Pending
- 2007-05-01 CA CA2651300A patent/CA2651300C/en active Active
- 2007-05-01 DK DK07761644.9T patent/DK2026764T3/en active
-
2013
- 2013-08-20 JP JP2013170156A patent/JP2014014694A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009535422A5 (https=) | ||
| Lee et al. | Biodegradable implants for sustained drug release in the eye | |
| AU2019250153B2 (en) | Methods and biocompatible compositions to achieve sustained drug release in the eye | |
| JP2008540552A5 (https=) | ||
| CN111743878B (zh) | 用于眼科应用和/或其它应用的组合物以及方法 | |
| TWI542338B (zh) | 用於活性劑之控制釋放的眼用裝置 | |
| JP5696121B2 (ja) | α−２アドレナリン受容体アゴニスト含有生分解性眼内インプラント | |
| AU2013256092B2 (en) | Pharmaceutical nanoparticles showing improved mucosal transport | |
| JP2007535539A5 (https=) | ||
| JP2018171519A (ja) | 持続型薬物送達インプラント | |
| WO2011109384A2 (en) | Biodegradable polymers for lowering intraocular pressure | |
| JP2012521997A5 (https=) | ||
| TW200826943A (en) | Intraocular drug delivery systems | |
| JP2023120431A (ja) | 眼の症状の治療のための硝子体内薬物送達システム | |
| CN114980861A (zh) | 缓释药物递送装置 | |
| JP2007535564A5 (https=) | ||
| Andonova | Synthetic polymer-based nanoparticles: Intelligent drug delivery systems | |
| TW202345803A (zh) | 由投予眼部藥物遞送插入物預防老年黃斑部病變之方法 | |
| AU2019245436B2 (en) | Ophthalmic drug sustained release formulation and uses for dry eye syndrome treatment | |
| HK40039406B (en) | Compositions and methods for ophthalmic and/or other applications | |
| HK40039407A (en) | Compositions and methods for ophthalmic and/or other applications | |
| CN118591369A (zh) | 挤出式眼部插入物或植入物及其方法 | |
| Mack et al. | A Biodegradable Fiber for Controlled Delivery of Therapeutics to the Eye | |
| HK1226949A1 (en) | Compositions and methods for ophthalmic and/or other applications |